South Korea
· Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 457.38 billion. The enterprise value is 431.04 billion.
| Market Cap | 457.38B |
| Enterprise Value | 431.04B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 10.54 million shares outstanding. The number of shares has increased by 18.04% in one year.
| Shares Outstanding | 10.54M |
| Shares Change (YoY) | +18.04% |
| Shares Change (QoQ) | +4.43% |
| Owned by Insiders (%) | 16.05% |
| Owned by Institutions (%) | 0.12% |
| Float | 5.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.18 |
| PB Ratio | 6.08 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -40.87 |
| EV / Sales | 32.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -34.00 |
Financial Position
The company has a current ratio of 5.38, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.38 |
| Quick Ratio | 4.86 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.63 |
| Interest Coverage | -25.30 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 630.58M |
| Profits Per Employee | -502.28M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 35,021.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 64.94 |
| Average Volume (20 Days) | 469,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 13.24 billion and -10.55 billion in losses. Loss per share was -2,610.23.
| Revenue | 13.24B |
| Gross Profit | 13.23B |
| Operating Income | -15.16B |
| Pretax Income | -11.91B |
| Net Income | -10.55B |
| EBITDA | -10.25B |
| EBIT | -15.16B |
| Loss Per Share | -2,610.23 |
Balance Sheet
The company has 43.32 billion in cash and 8.04 billion in debt, giving a net cash position of 35.29 billion or 3,348.55 per share.
| Cash & Cash Equivalents | 43.32B |
| Total Debt | 8.04B |
| Net Cash | 35.29B |
| Net Cash Per Share | 3,348.55 |
| Equity (Book Value) | 84.01B |
| Book Value Per Share | 7,137.33 |
| Working Capital | 40.36B |
Cash Flow
In the last 12 months, operating cash flow was -12.62 billion and capital expenditures -56.82 million, giving a free cash flow of -12.68 billion.
| Operating Cash Flow | -12.62B |
| Capital Expenditures | -56.82M |
| Free Cash Flow | -12.68B |
| FCF Per Share | -1,202.95 |
Margins
Gross margin is 99.88%, with operating and profit margins of -114.45% and -79.65%.
| Gross Margin | 99.88% |
| Operating Margin | -114.45% |
| Pretax Margin | -89.97% |
| Profit Margin | -79.65% |
| EBITDA Margin | -77.42% |
| EBIT Margin | -114.45% |
| FCF Margin | -95.74% |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.04% |
| Shareholder Yield | -18.04% |
| Earnings Yield | -6.01% |
| FCF Yield | -2.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
D&D Pharmatech has an Altman Z-Score of 3.97.
| Altman Z-Score | 3.97 |
| Piotroski F-Score | n/a |